Navigation Links
Immucor Announces Fiscal Third Quarter Results
Date:4/6/2009

Company operates and its adverse impact on reported results; the inability of the Company's Japanese, French and United Kingdom subsidiaries to attain expected revenue, gross margin and net income levels; the outcome of any legal claims or regulatory investigations known or unknown, including the ongoing FTC investigation; the Company's inability to protect its intellectual property or its infringement of the intellectual property of others; lower than expected market acceptance of the molecular immunohematology products produced by BioArray; the unexpected application of different accounting rules; general economic conditions; and adverse developments with respect to the operation or performance of the Company, its products and its affiliates or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this Press Release can be found in the Company's Risk Factor disclosures in its Form 10-K for the year ended May 31, 2008, and its Form 10-Q for the quarter ended February 28, 2009. Immucor assumes no obligation to update any forward-looking statements.


                                   IMMUCOR, INC.
                      CONDENSED CONSOLIDATED STATEMENTS OF INCOME
                    (Unaudited, in thousands except per share data)

                                     Three Months Ended    Nine Months Ended
                                      Feb. 28,  Feb. 29,   Feb. 28,   Feb. 29,
                                        2009      2008       2009       2008

    NET SALES                         $75,309   $67,029   $221,506   $192,585
    COST OF SALES                      21,520    18,688     60,734     56,489
    GROSS PROFIT                       53,789    48,341    160,772    136,096

    OPERATING EXPENSES
     Research and development           2,777     1,522      7,553      5,011
     Selling and marketing              9,355 
'/>"/>
SOURCE Immucor, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Immucor Announces New Vice President, Operations
2. Immucor Announces Fiscal Second Quarter Results; Raises Fiscal 2009 EPS Guidance
3. Immucor Closes BioArray Acquisition
4. Immucor Schedules Fiscal 2009 Guidance Call
5. Immucor Responding to FDA Warning Letter
6. Immucor Announces Record Fiscal Third Quarter Results
7. Immucor Schedules Third Quarter Earnings Release and Conference Call
8. Immucor, Inc. Adds Director to Board
9. Immucor Announces Update to Second Quarter Conference Call Number
10. Immucor, Inc. Appoints New Chief Financial Officer
11. Immucor Announces Record Fiscal First Quarter Revenues
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... NH 9/18/14) A leading Dartmouth researcher, working with The ... a paper published today in the Journal of ... increase the risk of melanoma. , "For the first ... length of these telomeres play a part in the ... study Mark Iles, PhD, School of Medicine at the ...
(Date:9/19/2014)... September 19, 2014 According to a ... the embattled blood-thinner Xarelto, named as defendants in several ... Pleas, have moved the court to dismiss those suits ... have sufficient connection with Philadelphia.* The cases include, for ... (No. 140304328; Pa. Comm. Pls., Philadelphia Cty.), which was ...
(Date:9/19/2014)... 19, 2014 (HealthDay News) -- U.S. military troops deployed ... skin cancer, according to a new study. ... researchers revealed. In some cases, military personnel developed blisters ... color, shape or size of their moles since being ... risk factors for skin cancer, the study authors noted. ...
(Date:9/19/2014)... Sept. 19, 2014 (HealthDay News) -- Pregnant women who live ... or low birth weight babies, a new study suggests. ... Canada, and found that expectant mothers who lived in a ... a 20 percent lower risk of very preterm birth (before ... preterm birth (30 to 36 weeks). Babies born to ...
(Date:9/19/2014)... Sept. 19, 2014 (HealthDay News) -- The U.S. Food and ... on Thursday. Trulicity is part of a class of once-a-week ... with type 2 diabetes. "Trulicity is a new ... existing treatment regimens to control blood sugar levels in the ... director of the FDA,s Office of Drug Evaluation II, said ...
Breaking Medicine News(10 mins):Health News:Melanoma risk found to have genetic determinant 2Health News:Xarelto Makers Seek Dismissal of Cases Brought in Philadelphia, Notes Rottenstein Law Group LLP 2Health News:Xarelto Makers Seek Dismissal of Cases Brought in Philadelphia, Notes Rottenstein Law Group LLP 3Health News:Some U.S. Troops May Face Greater Skin Cancer Risk 2Health News:Do Greener Neighborhoods Produce Healthier Babies? 2Health News:FDA Approves Another Weekly Injectable Drug for Type 2 Diabetes 2
... associated with additional injury leading to structural and ... The injury induced during reperfusion is evolved a ... upon reoxygenation and a delayed phase. It is ... induces a cascade of series of cellular events ...
... blood clots are often recommended to stop these medications ... However, interruption of these medications can place patients at ... by Shai Friedland at the VA Palo Alto hospital ... without interrupting anticoagulation. Their study will be published on ...
... continuity after gastric resection. It seems that insufficient attention ... conditions affect the gastroduodenal system after distal gastric resection. ... duodenal suture dehiscence, but still many pathological mechanisms involved ... research article to be published on April 28, 2009 ...
... several other institutions worldwide, have pinpointed for the first ... endemic and epidemic mosquito-borne illness that is a rapidly ... The study, published in the May issue of ... the direct and indirect costs of dengue cases in ...
... Work, Money and the EconomySeven out of 10 ... 7 Economic pressures are having an increasing ... to a new survey by the American Psychological ... reporting significant stress related to work, money, housing ...
... of Directors of Tyco International Ltd. (NYSE: TYC ... (CHF) per share, payable on August 26, 2009, to shareholders ... 2009, subject to a required filing with the Swiss Commercial ... second installment of an annual dividend of CHF 0.93 per ...
Cached Medicine News:Health News:A new light on the mechanisms of early stage liver reperfusion injury 2Health News:Dengue fever costs billions in health care, lost productivity and absenteeism 2Health News:APA Poll Finds Economic Stress Taking a Toll on Men 2Health News:APA Poll Finds Economic Stress Taking a Toll on Men 3
(Date:9/19/2014)... WASHINGTON , Sept. 19, 2014 /PRNewswire-USNewswire/ ... often used to inflate sales of brand drugs ... Part D,  according to a new report ... Services Office of the Inspector General (OIG). Federal anti-kickback ... sales of goods that are subsidized by the ...
(Date:9/19/2014)... DALLAS , Sept. 19, 2014 ... Market Outlook to 2020″, provides key ... General Surgery devices market. The report ... dollars, and volume (in units) within ... Cystoscopes, Colonoscopes, Sigmoidoscopes, Esophagoscopes & Gastroscopes, ...
(Date:9/19/2014)... September 19, 2014 According ... Equipment (Cryotherapy, Heat, therapy, Hydrotherapy), Accessories (Posture Mirror, Exercise ... Advanced technologies - Global Forecast to 2019" published ... to reach $19,786.3 Million by 2019 from $14,240.0 ... from 2014 to 2019. Browse 74 ...
Breaking Medicine Technology:PCMA: New OIG Report Cites Drug Manufacturer "Copay Coupon" Use in Medicare Part D 2United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 2United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 3United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 4United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 5Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 2Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 3Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 4
... data presented today at the Society for Cardiovascular ... first to look at the use of highly ... detect restricted blood flow to the heart in ... Preliminary results from the ST-DETECT Trial using high-fidelity ...
... a compression clothing distributor, recently added three new ... Medical, Solaris and Gottfried are now available online through ... are used in lymphedema treatment. Lymphedema is a medical ... hands. Although it can be caused by a genetic ...
Cached Medicine Technology:New Data Provide First Look at Ability to Detect Life-Threatening Heart Problems in Some High-Risk Patients 2New Data Provide First Look at Ability to Detect Life-Threatening Heart Problems in Some High-Risk Patients 3BrightLife Direct Introduces 3 New Lymphedema Product Lines 2
Inquire...
... Used for the injection of contrast ... The dual lumen design eliminates the need ... designed to promote atraumatic passage into and ... layer of hydrophilic polymer that when activated, ...
Used for retrograde pyelogram. Supplied sterile in peel-open packages. Intended for one-time use....
Used for the retrieval of stones, stents, or other objects in the urinary tract under direct vision. Retrieval Forceps are designed for use through rigid or flexible endoscopes. Supplied sterile in p...
Medicine Products: